Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NeuBase Therapeutics Announces Addition of Industry Pioneer Dr. Samuel Broder and World-Renowned Geneticist Dr. George Church to Scientific Advisory Board
Experts from Harvard and National Cancer Institute to aid in development of novel antisense oligonucleotide therapies for genome-wide transcriptional regulation
PITTSBURGH, July 30, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the addition of Samuel Broder, M.D, Ph.D. and George Church, Ph.D. to its scientific advisory board (SAB), bringing additional expertise in genetics, genomics, and oncology to a team already recognized for leadership in neurology, genomics and therapeutic development. The SAB will work closely with the NeuBase management team as the Company advances its next-generation gene regulating therapies through development, first in genetic diseases such as the repeat expansion disorders Huntington’s disease and myotonic dystrophy, as well as oncology, and then more broadly.
“We are privileged to have such illustrious colleagues join us as founding members of our scientific advisory board,” said Dietrich Stephan, Ph.D., chief executive officer of NeuBase. “Drs. Broder and Church are each renowned and respected experts in their fields and recognize the immense potential of the PATrOL™ platform to transform millions of lives and fulfill the promise of the Human Genome Project. We are looking forward to utilizing their expertise as we advance the first PATrOL™-enabled therapies for patients suffering from Huntington’s disease and myotonic dystrophy, as well as ultimately helping those suffering from other diseases such as cancer.”
Dr. Danith Ly, chief scientific officer of NeuBase, added, “I am thrilled to welcome Drs. Broder and Church to our SAB. We believe that antisense approaches are the answer to treating a range of genetic diseases, and NeuBase’s PATrOL™ platform represents the future of antisense therapies. I am confident that the expertise Dr. Broder and Dr. Church bring to the table will perfectly complement our team, which is recognized for its leadership in neurology, genomics and therapeutic development, and will help NeuBase bring our PATrOL™-enabled therapies to patients who so desperately need them.”
Dr. Broder is the former Director of the National Cancer Institute (NCI). He was appointed to the position by President Ronald Reagan in 1989 and served through 1995. While at the NCI, he oversaw the development of numerous anti-cancer therapeutic agents, helped launch a number of large-scale clinical trials related to the prevention, diagnosis and treatment of cancer and inaugurated the highly successful Specialized Programs of Research Excellence (SPORE) program. His laboratory played a major role in developing the first three agents approved by FDA specifically to treat AIDS: Retrovir® (AZT), Videx® (ddI) and HIVID® (ddC) and laid the foundation for many other therapies. As the executive vice president for medical affairs and chief medical officer at Celera Corporation, he helped advance Celera’s Human Genome Project, culminating in generating the blueprint of the human genome which has enabled many of the advances in the current life sciences industry. Most recently, he served as senior vice president and health sector head at Intrexon Corporation with a focus on novel gene therapies. He was elected to the National Academy of Medicine of the National Academies of Sciences, Engineering, and Medicine in 1993.
Dr. Church is a pioneer of genome engineering, DNA sequencing and synthetic biology. He brings significant expertise both in genetics and the biotechnology industry to the NeuBase SAB. He has cofounded 24 biotechnology companies, authored over 500 papers and 140 patent publications. Dr. Church is professor of genetics at Harvard Medical School, and professor of health sciences and technology at Massachusetts Institute of Technology and Harvard Medical School. He is the director of the Center for Genomically Engineered Organs (CGEO), the Harvard DOE Technology Center, the Lipper Center for Computational Genetics and is a founding core member of the Wyss Institute for Biologically Inspired Engineering. Dr. Church is a member of the National Academy of Sciences (2011) and the National Academy of Engineering (2012) and has received the Franklin Institute’s Bower Award for Achievement in Science (2011). He holds a Ph.D. in biochemistry and molecular biology from Harvard University.
About NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL™ technology, NeuBase aims to first tackle rare, genetic neurological disorders.
NBSE - other filers today including the CEO
CEO has 34% of the company which also includes options
5,859,569
(1) Includes 3,311,930 shares of Common Stock of which Dr. Stephan has the right to acquire beneficial ownership within 60 days of July 22, 2019 through the exercise of options.
(2) Shares held directly by Lipizzaner LLC, of which Dr. Stephan is the sole member.
Shivaji Thadke
I think chief scientist
6%
1,019,055
Carnegie Mellon University 13G
939,412
5.5%
OHRP now NBSE
short interview with CEO
Enough financing for 12-24 months, before trials
https://tdameritradenetwork.com/video/rB4AoWvoE9qBa_waRPYCOw
twitter
https://twitter.com/NeuBaseInc
NeuBase +4.3% after Einhorn disclosure
Jul. 16, 2019 6:38 PM ET|About: NeuBase Therapeutics, Inc. (NBSE)|By: Jason Aycock, SA News Editor
NeuBase Therapeutics (NASDAQ:NBSE) is up 4.3% after hours following an ownership disclosure from David Einhorn's Greenlight Capital.
In the filing, Einhorn discloses beneficial ownership of 1,538,462 shares of common stock, making up a 9% stake.
The stock closed up 2% today; it began trading as a combined company with Ohr Pharmaceuticals yesterday, following the two companies' merger.
https://seekingalpha.com/news/3478276-neubase-plus-4_3-percent-einhorn-disclosure
* * $OHRP Video Chart 07-12-2019 * *
Link to Video - click here to watch the technical chart video
* * $OHRP Video Chart 03-06-2019 * *
Link to Video - click here to watch the technical chart video
* * $OHRP Video Chart 02-07-2019 * *
Link to Video - click here to watch the technical chart video
Trading pattern looks like this has everything to do with the pending merger. Volume is huge. Time Will tell
Hey good luck brothas!
Yeah - I'm guessing peeps are playing it to recoup losses. Not convinced it's a real run on the merger. Time will tell.
NP
Probably... I got out just in time since I’ve been burnt 3 times already with RS’s.
I hear ya. I was in for 10 gs when the negative results were reported last January. Was about to say screw it and dump when the merger was announced. Now I'm just holding to see what happens.
GLTY
NP
One other thing that burns my ass, there’s no news to be found anywhere I could think of for today’s price action, it seems that we are always the last to get any info, ya know.....WTF.
Hey there’s a first time for everything, never seen this before on a R/S yeah I panicked and sold. I was in it for over 37 thousand bucks, had already lost 2/ 3rds of my money so @ 3.20 or so I missed out on about 3 gs..... unless it keeps going. You know how it is when you’re in this type of situation you just don’t want to go back and look cuz you’ll just make yourself sick.
Starting to think he might have been a bit premature jumping out
Your Welcome! Just need to find the next big opportunity now.
Thanx for that Make, good luck with all your trades!
Lol... Sometimes it’s just best to take a loss and move on. Glad you did well on the other stock.
See that, best interest of the shareholders my ass, here it goes down, down, down. I have yet to see a R/S benefit any one but the executives at the board, the insiders. Man I’m I glad I sold for a big loss beforehand, I still managed to save over 10k and reinvested it in that bankruptcy stock BioAmber, right now I more than tripled my investment. So OHRP can blow me!!!!!!
I’ve owned my shares beforehand, but don’t want to sell because of the nay sayers, like today lots of buying and the share price continues up, someone knows something.
I didn’t realize that it would be pumped a little, I panicked and sold, I’m in that Bio Amber bankruptcy company with 1.5 mm shares and they have been going back and for for months now. Some say shares will be cancelled while some say the shares will be bought out, and some are talking about a reverse merger. I did as much DD as possible and still don’t know what the outcome will be. Could make out really good or get screwed again I don’t know man this is nerve racking to say the least.
Sorry to hear that. I’ve been through 3 RS with different companies and got screwed. As soon as I heard this was going to RS I placed a sell order. I had a feeling it was going to get pumped before the RS.
Nice to see a few got out unscaved, I on the other hand got killed here. I bought in at .38 for 98K shares and sold under .11 saved 1 3rd of my investment. I just love the way the company tells us the R/S is in the best interest of the share holders, this is my fifth R/S and didn’t recove one cent so I was not going to hold on and hope something would turn out differently. Oh well on to the next one LOL!!!
I was able to pull my money out before RS. I’m so glad it hit .137 today. No loss for me.. On to the next one.
So much for that - RS approved 1 for 20:
https://ir.ohrpharmaceutical.com/press-releases/detail/497
I voted no R/S, with the merger they don't need to split, I'd like to keep the shares I have thank you!!!
* * $OHRP Video Chart 01-03-2019 * *
Link to Video - click here to watch the technical chart video
Annual Report out - note about RS:
The Company has filed a definitive proxy statement in connection with special meeting of stockholders to be held on January 18, 2019, at which the Company’s stockholders will vote to approve an amendment to the Company’s certificate of incorporation to effect a reverse stock split of the Company’s common stock at a split ratio of not less than one-for-three and not more than one-for-twenty, to be effective, if at all, at such time as the Company’s Board of Directors shall determine in its sole discretion. We cannot provide any assurances that the stockholders will approve the reverse stock split at the special meeting.
So the shareholders could deny it, in light of the announced merger. Nothing so far has been canceled.
There's so much going on with this ticker and there's no one here posting anything. But some of these worthless scam ripoff stocks the boards are blowing up, I don't get it.
yeah thats what i thought....
I've been stung with 5 R/S so far in the last few years only to have lost most of the shares in those stocks.
Then to watch them tank back down to below the price before the R/S. Sure would be nice to see them cancel it, I've never seen a company announce a R/S and then announce a merger a few weeks later.
I received the proxy yesterday to vote on the R/S so I think they have to, if the stock some how makes it to a buck a share then they wouldn't have to. But that's a long way to go.
will there still be a R/S ?????
Correction....... "after" the R/S.
MERGER !!!!!!!!! Right before a R/S .....go figure.
Oh how nice, another screwing I'll be left with 49 shares and by the time they let us trade this again the shares will be worth .0003
10q out today meeting in january voting on 1 - 20 R/S wtf merry christmas
( OHRP ) ~ BusinessWire, GlobeNewswire and PR Newswire News
OHR Pharmaceutical Inc OHRP:NASDAQ
Wet Age-related Macular Degeneration Pipeline Insights Report - Leading Companies in this Space are Novartis, OHR Pharmaceutical, Allergan and Opthotech - ResearchAndMarkets.com
BusinessWire
4:50 AM ET
The "Wet Age-related Macular Degeneration - Pipeline Insights, 2017" drug pipelines has been added to ResearchAndMarkets.com's offering.
Wet Age-related Macular Degeneration - Pipeline Insights, 2017 provides comprehensive insights about pipeline drugs across this indication. This report further provides information on the therapeutic development of more than 20+ pipeline drugs at various stages covering Phase III, Phase II and Phase I and contains a comparative assessment by product type, route of administration and molecule type.
More than half of the clinical products are undergoing Phase II clinical studies and three had entered late stage (Phase III) of development. The report also provides list of 25+ (Pre-clinical and Discovery) products. Further, The report contains list of the 25+ dormant products in this space. Leading companies in this space are Novartis, OHR Pharmaceutical, Allergan and Opthotech.
Comparative analysis of pipeline drugs at various stages and their therapeutic assessment by product type and molecule type provides additional and vital details of the pipeline drugs. Information on various technologies involved in the development of pipeline therapeutics along with all the collaborations and agreements of the res pective company brings added the advantage of this report. Patent and Financing details related to the products are also provided.
Key Topics Covered:
Overview Age-Related Macular Degeneration Risk factors for AMD Wet AMD - Pathogenesis Wet AMD - Clinical Features & Diagnosis Wet AMD - Treatment Options Pipeline Therapeutics (Active Products) Comparative Analysis Late Stage Products (Phase III) Comparative Analysis Abicipar: Allergan DE-122: Santen Pharmaceutical AS101: BioMAS Product Description Research and Development More drugs in detailed report Pre-clinical & Discovery Stage Products Therapeutic Assessment: Active Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type
Companies Mentioned
Acucela Adalta Adverum Biotechnologies Aerie Pharmaceuticals Allergan Benitech Biopharma Charlesson Coherus Biosciences Daiichi Sankyo GreyBug Vision Hemera Biosciences MeiraGTx Novartis Ocular Therapeutix OHR Pharmaceutical Opthotech Corporation Oxford Biomedica PanOptica pSivida Quark Regeneron Roche RXI Pharmaceuticals SciFluor Life Sciences
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fs72ll/wet_agerelated?w=4
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20181203005353r1&sid=cmtx6&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/201 81203005353/en/
SOURCE: Research and Markets
ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900Related Topics: Optical Disorders Drugs
Any news on shareholder meeting?
$OHRP - PPS increase 25 percent on huge volume. No news out so the question is WHY?
Sure seems like someone knows something. Board meeting Sept. 28
* * $OHRP Video Chart 09-11-18 * *
Link to Video - click here to watch the technical chart video
Followers
|
27
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
612
|
Created
|
11/27/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |